share_log

EyePoint Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

EyePoint Pharmaceuticals | 144:拟议出售证券

美股SEC公告 ·  01/23 00:00

Moomoo AI 已提取核心信息

EyePoint Pharmaceuticals, Inc. Director Nancy Lurker is set to sell 5,044 shares of common stock on 01/23/2024, as per the latest SEC filings. The shares to be sold have an aggregate market value of approximately $125,949.69. The securities were acquired through open market purchases and stock options between October 2019 and February 2020. This planned sale follows a previous transaction where Lurker sold 20,000 shares for a total gross proceed of $415,164 on 12/04/2023.
EyePoint Pharmaceuticals, Inc. Director Nancy Lurker is set to sell 5,044 shares of common stock on 01/23/2024, as per the latest SEC filings. The shares to be sold have an aggregate market value of approximately $125,949.69. The securities were acquired through open market purchases and stock options between October 2019 and February 2020. This planned sale follows a previous transaction where Lurker sold 20,000 shares for a total gross proceed of $415,164 on 12/04/2023.
根据美国证券交易委员会的最新文件,EyePoint Pharmicals, Inc.董事南希·卢克定于2024年1月23日出售5,044股普通股。待售股票的总市值约为125,949.69美元。这些证券是在2019年10月至2020年2月期间通过公开市场购买和股票期权收购的。此次计划出售是在之前的一笔交易之后进行的,在该交易中,Lurker于2023年4月12日出售了20,000股股票,总收益为415,164美元。
根据美国证券交易委员会的最新文件,EyePoint Pharmicals, Inc.董事南希·卢克定于2024年1月23日出售5,044股普通股。待售股票的总市值约为125,949.69美元。这些证券是在2019年10月至2020年2月期间通过公开市场购买和股票期权收购的。此次计划出售是在之前的一笔交易之后进行的,在该交易中,Lurker于2023年4月12日出售了20,000股股票,总收益为415,164美元。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息